Arcellx Inc (ACLX) Price & Analysis

Compare

266 Followers

ACLX Stock Chart & Stats

$69.56

-$3.36(-4.36%)

At close: Jan 08 4:00 PM EST

$69.56

-$3.36(-4.36%)

Day’s Range― - ―

52-Week Range$47.86 - $94.07

Previous CloseN/A

Volume227.93K

Average Volume (3M)883.90K

Market Cap

$4.02B

Enterprise Value$4.24B

Total Cash (Recent Filing)$461.38M

Total Debt (Recent Filing)$51.79M

Price to Earnings (P/E)―

Beta1.03

Next Earnings

Feb 26, 2026

EPS Estimate

-1.06

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.99

Shares Outstanding57,822,872

10 Day Avg. Volume1,564,169

30 Day Avg. Volume883,896

Financial Highlights & Ratios

PEG Ratio-1.06

Price to Book (P/B)9.03

Price to Sales (P/S)38.06

P/FCF Ratio-42.39

Enterprise Value/Market Cap1.05

Enterprise Value/Revenue118.01

Enterprise Value/Gross Profit5.23K

Enterprise Value/Ebitda-20.22

Forecast

1Y Price Target

$114.71

Price Target Upside64.91% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering17

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Financial OutlookArcellx is well positioned to achieve profitability at much lower revenue levels versus Legend, who will incur a net collaboration revenue loss despite almost ~$2B in sales.

Market PositionAnalysts see differentiation on safety and delivery, alongside effective non-inferiority on efficacy for anito-cel amongst MM CAR-Ts, which should position the product for commercial success following likely approval in the US.

Safety ProfileAnito-cel maintains 'safer Carvykti' profile with strong PFS/OS and no delayed neurotoxicity or enterocolitis seen to date.

Bears Say

Infection RiskThe presence of 54% grade 3/4 infections in the data is a concern for the use of CAR-Ts.

Market SentimentACLX shares experienced significant pressure due to competitor data from the MajesTEC-3 trial.

Trial Data ConcernsThe MajesTEC-3 trial data weighed on ACLX shares, adding to the debate on the use of CAR-Ts versus bispecifics in multiple myeloma treatment.

Arcellx Inc News

Arcellx announces new data for its iMMagine-1 study in patients with RRMM

Arcellx (ACLX) announced new positive data from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel, in patients...

1d ago

ACLX

GILD

Gilead’s Kite announces new data for iMMagine-1 Study at ASH 2025

Kite, a Gilead Company (GILD), and its partner Arcellx (ACLX) announced new positive data from its pivotal iMMagine-1...

1d ago

ACLX

GILD

Kelonia data too early to read to Gilead, Arcellx’s anito-cel, says BMO Capital

BMO Capital says Phase 1 data from three patients in Kelonia Therapeutics’ inMMyCAR study “look interesting,” with all...

14d ago

ACLX

GILD

Citi says Arcellx weakness on ‘highly preliminary’ Kelonia data an overreaction

Citi believes today’s weakness in Arcellx (ACLX) is “an overreaction to the highly preliminary” Phase 1 inMMyCAR data...

14d ago

ACLX

Arcellx weakness on competitive worries ‘overdone,’ says Guggenheim

Guggenheim analyst Michael Schmidt notes Arcellx (ACLX) shares are under pressure this afternoon following disclosure of a late-breaking...

14d ago

ACLX

Arcellx initiated with a Peer Perform at Wolfe Research

Wolfe Research initiated coverage of Arcellx (ACLX) with a Peer Perform rating and no price target The firm’s...

21d ago

ACLX

Promising Clinical Data and Favorable Safety Profile Drive Buy Rating for Arcellx Inc

Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on Arcellx Inc. The associated price target...

8h ago

ACLX

Arcellx Inc’s Promising Future: Buy Rating Backed by Strong Efficacy, Safety, and Strategic Partnerships

William Blair analyst Sami Corwin has maintained their bullish stance on ACLX stock, giving a Buy rating today....

10h ago

ACLX

Arcellx Inc’s Anito-cel: Promising CAR-T Therapy with Superior Safety Profile and Market Readiness

Needham analyst Gil Blum has maintained their bullish stance on ACLX stock, giving a Buy rating today. Gil...

10h ago

ACLX

Arcellx Inc’s Promising iMMagine-1 Study and Strategic Plans Justify Buy Rating and $112 Price Target

Bank of America Securities analyst Jason Gerberry has maintained their bullish stance on ACLX stock, giving a Buy...

20h ago

ACLX

Optimistic Buy Rating for Arcellx Inc: Promising Anito-cel Therapy and Strategic Advancements

Analyst Judah Frommer from Morgan Stanley maintained a Buy rating on Arcellx Inc and keeping the price target...

20h ago

ACLX

Arcellx Inc’s Anito-cel: A Promising CAR-T Therapy with Strong Market Positioning and Growth Potential

Morgan Stanley analyst Judah Frommer has maintained their bullish stance on ACLX stock, giving a Buy rating yesterday....

12d ago

ACLX

Promising Outlook for Arcellx Inc’s Anito-cel Therapy in Multiple Myeloma Treatment

Bank of America Securities analyst Jason Gerberry maintained a Buy rating on Arcellx Inc yesterday and set a...

13d ago

ACLX

Arcellx Inc’s Strategic Advantage in Gilead Partnership Drives Buy Rating and $130 Price Target

John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on Arcellx Inc. The associated price target...

18d ago

ACLX

ACLX FAQ

What was Arcellx Inc’s price range in the past 12 months?

Arcellx Inc lowest stock price was $47.86 and its highest was $94.07 in the past 12 months.

What is Arcellx Inc’s market cap?

Arcellx Inc’s market cap is $4.02B.

When is Arcellx Inc’s upcoming earnings report date?

Arcellx Inc’s upcoming earnings report date is Feb 26, 2026 which is in 80 days.

How were Arcellx Inc’s earnings last quarter?

Arcellx Inc released its earnings results on Nov 05, 2025. The company reported -$0.99 earnings per share for the quarter, missing the consensus estimate of -$0.983 by -$0.007.

Is Arcellx Inc overvalued?

According to Wall Street analysts Arcellx Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Arcellx Inc pay dividends?

Arcellx Inc does not currently pay dividends.

What is Arcellx Inc’s EPS estimate?

Arcellx Inc’s EPS estimate is -1.06.

How many shares outstanding does Arcellx Inc have?

Arcellx Inc has 57,822,872 shares outstanding.

What happened to Arcellx Inc’s price movement after its last earnings report?

Arcellx Inc reported an EPS of -$0.99 in its last earnings report, missing expectations of -$0.983. Following the earnings report the stock price went up 0.788%.

Which hedge fund is a major shareholder of Arcellx Inc?

Currently, no hedge funds are holding shares in ACLX

Arcellx Inc Stock Smart Score

Outperform

Fundamentals

Return on Equity

-47.18%

Trailing 12-Months

Asset Growth

-14.25%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Arcellx Inc

Arcellx Inc (ACLX) is a biotechnology company focused on developing innovative therapies for patients with cancer and other severe diseases. The company specializes in the development of its proprietary cell therapy platform, which leverages the unique properties of genetically engineered T cells to target and eliminate cancer cells. Arcellx is primarily engaged in the research, development, and commercialization of its lead product candidates, which are designed to address significant unmet medical needs in hematologic malignancies and other related conditions.

Arcellx Inc (ACLX) Earnings & Revenues

Historic Earnings Reports

ACLX Stock 12 Month Forecast

Average Price Target

$114.71

▲(64.91% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"59":"$59","78":"$78","97":"$97","116":"$116","135":"$135"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":134,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$134.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":114.71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$114.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":88,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$88.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[59,78,97,116,135],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,70.28,75.18153846153847,80.08307692307693,84.98461538461538,89.88615384615385,94.78769230769231,99.68923076923076,104.59076923076923,109.49230769230769,114.39384615384616,119.29538461538462,124.19692307692307,129.09846153846155,{"y":134,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,70.28,73.69769230769231,77.11538461538461,80.53307692307692,83.95076923076923,87.36846153846153,90.78615384615384,94.20384615384614,97.62153846153845,101.03923076923076,104.45692307692306,107.87461538461537,111.29230769230769,{"y":114.71,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,70.28,71.64307692307692,73.00615384615385,74.36923076923077,75.7323076923077,77.09538461538462,78.45846153846153,79.82153846153847,81.18461538461538,82.5476923076923,83.91076923076923,85.27384615384615,86.63692307692308,{"y":88,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":95.72,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.69,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.13,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.82,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.7,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.53,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.93,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.69,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.14,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.75,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.03,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.25,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.28,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >